Shopping cart processing ...
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Customer Support 24/7
USA/Canada Toll Free USA
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Your cart: $0.00 (0 items)

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!


  • Michael Brandtner Redding, CA, USA
    Thanks to my friends for suggesting me this site. Now I can order the drugs I am interested in without prescription and at lower cost.
More info »


Prednisolone is used for the treatment of allergy symptoms, breathing problems such as asthma, some blood diseases, collagen diseases such as lupus, some eye problems such as Keratit, cancer (leukosis), endocrine problems such as adrenal cells insufficiency, intestinal problems such as non specific ulcer colitis, edema or skin diseases such as psoriasis.

Brand: Prednisolone

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: May 2024
View product image
Package Price Per pill Save Order
Prednisolone 40 mg
360 pills - 40 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$219.93 $0.61 $415.47 Add to cart
270 pills - 40 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$193.84 $0.72 $282.71 Add to cart
180 pills - 40 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$141.65 $0.79 $176.05 Add to cart
120 pills - 40 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$105.57 $0.88 $106.23 Add to cart
90 pills - 40 mg $89.48 $0.99 $69.37 Add to cart
60 pills - 40 mg $71.23 $1.19 $34.67 Add to cart
30 pills - 40 mg $52.95 $1.77 No Add to cart
Prednisolone 20 mg
360 pills - 20 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$189.55 $0.53 $338.33 Add to cart
270 pills - 20 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$149.91 $0.56 $246.00 Add to cart
180 pills - 20 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$109.93 $0.61 $154.01 Add to cart
120 pills - 20 mg $81.99 $0.68 $93.97 Add to cart
90 pills - 20 mg $67.23 $0.75 $64.74 Add to cart
60 pills - 20 mg $54.17 $0.90 $33.81 Add to cart
30 pills - 20 mg $43.99 $1.47 No Add to cart
Prednisolone 10 mg
360 pills - 10 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$161.99 $0.45 $143.95 Add to cart
270 pills - 10 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$133.93 $0.50 $95.53 Add to cart
180 pills - 10 mg $98.91 $0.55 $54.06 Add to cart
120 pills - 10 mg $70.93 $0.59 $31.05 Add to cart
90 pills - 10 mg $57.95 $0.64 $18.54 Add to cart
60 pills - 10 mg $50.99 $0.85 No Add to cart
Prednisolone 5 mg
270 pills - 5 mg $97.95 $0.36 $72.83 Add to cart
180 pills - 5 mg $70.31 $0.39 $43.54 Add to cart
120 pills - 5 mg $53.91 $0.45 $21.99 Add to cart
90 pills - 5 mg $43.95 $0.49 $12.98 Add to cart
60 pills - 5 mg $37.95 $0.63 No Add to cart

Product description

Drug title


Pharmacological action

Prednisolone is a synthetic glucocorticoid drug, a dehydrated analog of hydrocortisone. It has anti-inflammatory, anti-allergic, immunosuppressive, antishock effect, increases sensitivity of β-adrenoreceptors to endogenous catecholamines.

It interacts with specific cytoplasmic receptors (all tissues have glucocorticoid receptors (GCS receptors), especially in liver) to form a complex that induces formation of proteins (including enzymes regulating vital processes in cells).

Anti-inflammatory action is associated with inhibition of release of inflammatory mediators by eosinophils and mast cells; induction of formation of lipocortins and reduction of the number of mast cells producing hyaluronic acid; reduction of capillary permeability; stabilization of cell membranes (especially lysosomal) and organelle membranes. Acts on all stages of the inflammatory process: inhibits the synthesis of prostaglandins (Pg) at the level of arachidonic acid (lipokortin inhibits phospholipase A2, suppresses the release of arachidonic acid and inhibits the biosynthesis of endoperoxides, leukotrienes that contribute to the processes of inflammation, allergy and other), synthesis of "pro-inflammatory cytokines" (including interleukin 1, FKF, and other). including interleukin 1, TNFα); increases resistance of cell membrane to the action of various damaging factors.

Influence on protein metabolism: reduces the number of globulins in blood plasma, increases the synthesis of albumin in the liver and kidneys (with an increase in the albumin/globulin ratio), reduces synthesis and increases protein catabolism in muscle tissue.

Influence on lipid metabolism: increases the synthesis of higher fatty acids and triglycerides, redistributes fat (fat accumulation occurs mainly in the shoulder girdle, face, abdomen), leads to hypercholesterolemia.

Effect on carbohydrate metabolism: increases the absorption of carbohydrates from the gastrointestinal tract; increases the activity of glucose-6-phosphatase (increased glucose flow from the liver into the blood); increases the activity of phosphoenolpyruvate carboxykinase and aminotransferase synthesis (activation of gluconeogenesis); promotes hyperglycemia.

Influence on water-electrolyte metabolism: inhibits sodium ions (Na+) and water in the body, stimulates excretion of potassium ions (K+) (mineralocorticoid activity), reduces the absorption of calcium ions (Ca2+) from the GIT, causes "washout" of calcium ions from bones and increases its renal excretion, reduces mineralization of bone tissue.

Immunosuppressive effect is caused by involution of lymphoid tissue, inhibition of lymphocyte proliferation (especially T-lymphocytes), suppression of B-cell migration and interaction between T- and B-lymphocytes, inhibition of cytokine release (interleukin-1, 2; interferon gamma) from lymphocytes and macrophages and reduction of antibody formation.

Anti-allergic action develops as a result of decreased synthesis and secretion of allergy mediators, inhibition of release of histamine and other biologically active substances from sensitized mast cells and basophils, decreased number of circulating basophils, suppression of lymphoid and connective tissue development, decreased number of T- and B-lymphocytes, mast cells, decreased sensitivity of effector cells to allergy mediators, suppression of antibody formation, changes in body's immune response.

In obstructive airways diseases the action is mainly caused by inhibition of inflammatory processes, prevention or reduction of mucous membrane edema severity, reduction of eosinophilic infiltration of submucous layer of bronchial epithelium and deposition of circulating immune complexes in bronchial mucosa, and also inhibition of mucous membrane erosion and desquamation. It increases sensitivity of β-adrenoreceptors of small and medium caliber bronchi to endogenous catecholamines and exogenous sympathomimetics, reduces mucus viscosity by reducing its production. It suppresses the synthesis and secretion of ACTH and secondary to the synthesis of endogenous GCS.



When administered orally, prednisolone is well absorbed from the gastrointestinal tract. Cmax in blood is reached 1-1.5 hours after oral administration.


Up to 90% of prednisolone is bound to plasma proteins: transcortin (cortisol-binding globulin) and albumin.


Prednisolone is metabolized in the liver, partially in the kidneys and other tissues, mainly by conjugation with glucuronic and sulfuric acids. Metabolites are inactive.


It is excreted with the bile and the kidneys by glomerular filtration and is 80-90% reabsorbed by the tubules. 20% of the dose is excreted unchanged by the kidneys. Blood plasma T1/2 after oral administration is 2-4 hours.

Contraindications to use

  • Hypersensitivity to prednisolone or to any of the excipients;
  • lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
  • systemic mycosis;
  • concomitant use of live and attenuated vaccines with immunosuppressive doses of the drug;
  • eye infection caused by herpes simplex virus (because of the risk of corneal perforation);
  • Breast-feeding period;
  • children under 3 years of age.

It is not recommended to use the drug in patients with acute or subacute myocardial infarction because of the risk of spreading of the focus of necrosis, delayed formation of scar tissue and, as a consequence, rupture of the heart muscle.


The drug should be used with caution in the following diseases and conditions:

Gastrointestinal diseases:

  • Gastric and duodenal ulcer;
  • esophagitis, gastritis;
  • Acute or latent peptic ulcer;
  • Recently established intestinal anastomosis;
  • Ulcerative colitis with threat of perforation or abscessing;
  • diverticulitis.

Parasitic and infectious diseases of viral, fungal, or bacterial nature (current or recent, including recent contact with an ill person):

  • herpes simplex;
  • Herpes zoster (viremic phase);
  • chicken pox;
  • measles;
  • amoebiasis;
  • strongyloidiasis;
  • active or latent tuberculosis.

Use in severe infectious diseases is admissible only against the background of specific antimicrobial therapy.

Pre- and post-vaccination period (8 weeks before and 2 weeks after vaccination), lymphadenitis after BCG vaccination. Immunodeficiencies (including AIDS or HIV infection).

Diseases of the cardiovascular system, including chronic heart failure, arterial hypertension, hyperlipidemia.

Endocrine disorders:

  • Diabetes mellitus (including impaired carbohydrate tolerance);
  • thyrotoxicosis;
  • hypothyroidism;
  • Obesity (III-IV stage).

Severe chronic renal or hepatic failure, nephrourolithiasis.

Hypoalbuminemia and conditions predisposing to its occurrence (liver cirrhosis, nephrotic syndrome).

Convulsive syndrome.

Elderly patients (high risk of osteoporosis and arterial hypertension).

Thromboembolic complications in the history or predisposition to the development of these conditions.

History of mental disorders, acute psychosis.

Systemic osteoporosis, myasthenia gravis, poliomyelitis (except for bulbar encephalitis), open and closed angle glaucoma.


In children during growth, GCS should be used only with absolute indications and under close supervision of the attending physician.

Use during pregnancy and lactation


Prednisolone readily crosses the placental barrier.

During pregnancy (especially in I trimester) or in women planning pregnancy the drug is indicated only when the expected therapeutic effect exceeds the risk of negative effect of prednisolone on mother and fetus. GCS should be administered during pregnancy only for absolute indications. If prolonged therapy during pregnancy, fetal growth is impaired. In the third trimester of pregnancy there is a risk of adrenal cortex atrophy in the fetus, which may require substitution therapy in the newborn. Children born to mothers who received prednisolone during pregnancy should be carefully evaluated for the timely detection of possible symptoms of adrenal insufficiency. There have been cases of cataracts in newborns whose mothers received GCS during pregnancy.

Close monitoring of pregnant women with gestosis in the second half of pregnancy, including preeclampsia after GCS use, is necessary.

The effect of GCS on the course and outcome of labor is unknown.

Breast-feeding period

Because GCSs penetrate into breast milk, if it is necessary to use the drug, breastfeeding should be discontinued.

Administration in patients with hepatic impairment

Caution should be exercised when using in case of severe hepatic insufficiency.

The drug has a stronger effect if the patient has cirrhosis of the liver.

Administration in patients with impaired renal function

It is recommended to treat the drug with caution in chronic renal failure.

Administration in children

Administration of the drug in children under 3 years of age is contraindicated.

In children during the period of growth, GKS should be used only in case of absolute indications and under close supervision of the attending physician.

Administration in elderly patients

Caution should be exercised when using in elderly patients (high risk of osteoporosis and arterial hypertension).

Indications of the drug Prednisolone

Systemic connective tissue diseases:

  • systemic lupus erythematosus;
  • scleroderma;
  • periarteritis nodosa;
  • dermatomyositis;
  • rheumatoid arthritis.

Acute and chronic inflammatory joint diseases:

  • Gouty and psoriatic arthritis;
  • Osteoarthritis (including post-traumatic);
  • polyarthritis;
  • Periarthritis brachialis;
  • Ankylosing spondylitis (Behterev's disease);
  • Rheumatoid arthritis, including juvenile rheumatoid arthritis;
  • Still's syndrome in adults;
  • bursitis;
  • nonspecific tenosynovitis;
  • synovitis;
  • epicondylitis.
  • Acute rheumatism, acute rheumatic heart disease.

Bronchial asthma.

Acute and chronic allergic diseases including:

  • Allergic reactions to drugs and food products;
  • serum sickness;
  • urticaria;
  • allergic rhinitis;
  • drug exanthema;
  • pollinosis, etc.

Skin diseases:

  • vesicles;
  • psoriasis;
  • eczema;
  • Atopic dermatitis (widespread neurodermatitis);
  • Contact dermatitis (with involvement of a large surface area of the skin);
  • toxiderma;
  • seborrheic dermatitis;
  • exfoliative dermatitis;
  • toxic epidermal necrolysis (Lyell's syndrome);
  • bullous herpetiform dermatitis;
  • Stevens-Johnson syndrome.

Cerebral edema (only after confirmation of symptoms of increased intracranial pressure by magnetic resonance imaging or computed tomography) due to a brain tumor and/or associated with surgery or radiation therapy, after parenteral administration of prednisolone.

Allergic eye disease:

  • Allergic forms of conjunctivitis.

Inflammatory eye disease:

  • Sympathetic ophthalmia;
  • Severe flaccid anterior and posterior uveitis;
  • optic neuritis.

Primary or secondary adrenal insufficiency (including conditions after adrenal removal). Hydrocortisone or cortisone are the drugs of choice; if necessary, synthetic analogs may be used in combination with mineralocorticosteroids; the addition of mineralocorticosteroids in children is especially important.

Congenital adrenal hyperplasia.

Kidney diseases of autoimmune genesis (including acute glomerulonephritis); nephrotic syndrome (including against the background of lipoid nephrosis).

Subacute thyroiditis.

Diseases of the blood and hematopoietic system:

  • agranulocytosis;
  • panmyelopathy;
  • autoimmune hemolytic anemia;
  • lymphatic and myeloid leukemia;
  • lymphogranulomatosis;
  • thrombocytopenic purpura;
  • secondary thrombocytopenia in adults;
  • Erythroblastopenia (erythrocytic anemia);
  • Congenital (erythroid) hypoplastic anemia.

Interstitial lung diseases:

  • acute alveolitis;
  • pulmonary fibrosis;
  • Stage II-III sarcoidosis.

Tuberculous meningitis, pulmonary tuberculosis, aspiration pneumonia (in combination with specific chemotherapy).

Berylliosis, Leffler syndrome (not amenable to other therapy), lung cancer (in combination with cytostatics).

Multiple sclerosis.

Gastrointestinal diseases:

  • ulcerative colitis;
  • Crohn's disease;
  • localized enteritis.

Prevention of transplant rejection reactions in organ transplants.

Hypercalcemia against the background of cancer.

Myeloma disease.

Dosing regimen

The drug is taken orally with a small amount of water.

The dose and duration of treatment is chosen by the doctor individually, depending on the indications and severity of the disease. The selection of the dose and duration of treatment is determined depending on the individual response to therapy.

It is recommended to take a full daily dose of the drug once or twice daily dose every other day with regard to circadian rhythm of endogenous GCS secretion between 6 and 8 a.m. The daily dose of Prednisolone should be taken after a meal (breakfast). The high daily dose can be divided into 2-4 doses, with a higher dose taken in the morning.

In acute conditions and as substitution therapy, an initial dose of 20-30 mg/day is prescribed for adults, with a maintenance dose of 5-10 mg/day. If necessary, the initial dose may be 15-100 mg/day, the maintenance dose is 5-15 mg/day.

For children aged 3 years and older, the initial dose is 1-2 mg/kg body weight per day in 4-6 doses, the maintenance dose is 0.3-0.6 mg/kg/day.

When therapeutic effect is achieved, the dose is gradually reduced by 5 mg, then by 2.5 mg at 3-5 day intervals, canceling the later doses first.

If the drug is used for a long time, the daily dose should be reduced gradually. Long-term therapy should not be stopped suddenly. Withdrawal of the maintenance dose is carried out the slower the longer the glucocorticoid therapy was used.

At stress influences (infection, allergic reaction, trauma, operation, nervous stress) in order to avoid aggravation of the basic disease, the dose of prednisolone should be temporarily increased (by 1.5-3 times, and in severe cases by 5-10 times).